Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes hospital-based therapies for acute life-threatening neurological conditions. Its lead product candidate, EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage (cSDH). The company also develops other product candidates, which are in pre-clinical development stages, including EG-1964, to prevent recurrent bleeding after treatment for cSDH; and EG-1963, to prevent rebleeding following surgeries outside the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.
200 Connell Drive
Berkeley Heights, NJ 07922
Founded in 2009
Edge Therapeutics, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Nov 6 15
Edge Therapeutics, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported loss from operations of $8,484,860 against $3,560,349 a year ago. Loss before income taxes was $10,130,050 against $3,518,133 a year ago. Net loss was $10,130,050 against $3,518,133 a year ago. Net loss attributable to common stockholders was $11,957,618 against $3,882,799 a year ago. Loss per share attributable to common stockholders basic and diluted was $7.08 against $2.30 a year ago.
For the nine months, the company reported loss from operations of $17,627,438 against $9,176,825 year ago. Loss before income taxes was $20,119,498 against $9,038,388 a year ago. Net loss was $20,119,498 against $9,038,388 a year ago. Net loss attributable to common stockholders was $24,376,581 against $10,120,495 a year ago. Loss per share attributable to common stockholders basic and diluted was $14.44 against $5.99 a year ago.
Edge Therapeutics, Inc. Appoints W. Bradford Middlekauff as Senior Vice President, General Counsel and Secretary
Nov 5 15
Edge Therapeutics, Inc. announced that W. Bradford Middlekauff has joined as Senior Vice President, General Counsel and Secretary, reporting to Brian A. Leuthner, President and Chief Executive Officer. Most recently, Mr. Middlekauff served as Executive in Residence at Princeton University and as Chief Business Officer and General Counsel for Transparency Life Sciences, LLC.
Edge Therapeutics Receives European Commission Orphan Drug Designation for EG-1962 in the Treatment of Patients with Subarachnoid Hemorrhage
Oct 12 15
Edge Therapeutics, Inc. announced that the European Commission (EC) has granted orphan drug designation to EG-1962, its lead product candidate, which is in development for treating patients that have suffered an aneurysmal subarachnoid hemorrhage (aSAH), also known as a ruptured brain aneurysm. The designation follows a positive opinion from the European Medicine Agency (EMA) Committee for Orphan Medicinal Products (COMP). Orphan drug designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment is currently available. In addition to a 10-year period of marketing exclusivity in the EU following product approval, receiving orphan drug designation provides incentives for companies seeking protocol assistance from the EMA during the product development phase, and direct access to the centralized authorization procedure.